Track topics on Twitter Track topics that are important to you
Japan’s Asahi Kasei has set up a German subsidiary based in Düsseldorf as a springboard for further expansion in Europe. Asahi Kasei Europe will start trading on Apr. 1 with a market capitaliza...
Asahi Kasei Corp.'s Asahi Kasei Pharma Corp. division will develop and commercialize Array BioPharma Inc.'s tropomyosin receptor kinase A (TrkA) inhibitors for pain, inflammation, and other indication...
Array BioPharm and Japan’s Asahi Kasei Pharma Corp have entered a strategic collaboration to develop…
Array BioPharma will partner with Asahi Kasei Pharma on the development and marketing of its tropomyosin receptor kinase A in -More-
Asahi Kasei Pharma has become the latest company to join forces with PeptiDream in a research deal.
Array BioPharma and Asahi Kasei Pharma announced a strategic collaboration to develop and commercialize select Tropomyosin receptor kinase A (TrkA) inhibitors, including Array-invented ARRY-954, for p...
* Co, Asahi Kasei Pharma corporation announce development and commercialization collaboration for novel pain and inflammation program
The authors conducted a study to assess the effects of yoga on blood pressure (BP). Patients were randomized to yoga (Blood Pressure Education Program [BPEP]), or a combined program (COMBO). Ambulator...
Inability to cross the occlusion with a guidewire is the most common cause of failure of coronary chronic total occlusion (CTO) interventions. We describe two cases of successful application of the no...
In this study, we investigate how measures of insulin secretion and other clinical information affect long-term glycemic control in patients with type 2 diabetes mellitus. Between October 2012 and Jun...